Abstract
The plasma concentrations of the enantiomers of halofantrine and its N-desbutyl metabolite in six patients with malaria were measured after oral administration of 3×750 mg doses of micronised, racemic halofantrine hydrochloride given at 6-hour intervals.
Significant differences were observed between the plasma concentrations of the enantiomers both of halofantrine and its N-monodesbutyl metabolite. AUC084h values were higher for (+)halofantrine (9917 μg·ml−1·h) than for (-)-halofantrine (6127 μg·ml−1·h).
The clinical significance of these observations is not known. The isomers have equipotent activity in vitro but their relative toxicity has not yet been assessed.
References
Broom C (1989) Human pharmacokinetics of halofantrine hydrochloride. In: Warhust DC, Schofield CJ (eds) Halofantrine in the treatment of multidrug resistant malaria. Elsevier, Amsterdam Cambridge, pp 15–20
Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J (1992a) In vitro activity of N-desbutyl derivative of halofantrine. Trans Roy Soc Trop Med Hyg 86: 12–13
Gimenez F, Aubry AF, Farinotti R, Kirkland K, Wainer IW (1992) The determination of the enantiomers of halofantrine and monodesbutylhalofantrine in plasma and whole blood using sequentiel achiral/chiral high performance liquid chromatography. J Biomed Pharm Anal 10: 245
Karbwang J, Ward SA, Milton KA, Na Bangchang K, Edwards G (1991) Pharmacokinetics of halofantrine in healthy Thai volunteers. Br J Clin Pharmacol 32: 639–640
Basco LK, Gillotin C, Gimenez F, Farinotti R, Le Bras J (1992b) In vitro activity of the enantiomers of mefloquine, halofantrine, and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol 33: 517–520
Karbwang J, Na Bangchang K, Bunnag D, Harinasuta T, Laothavorn P (1993) Cardiac effect of halofantrine — Lancet 342: 501
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gimenez, F., Gillotin, C., Basco, L.K. et al. Plasma concentrations of the enantiomers of halofantrine and its main metabolite in malaria patients. Eur J Clin Pharmacol 46, 561–562 (1994). https://doi.org/10.1007/BF00196116
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00196116